Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells

Natalia Nikolaeva1, Frederike J Bemelman, Si-La Yong

  • 1Department of Experimental Immunology, Academic Medical Centre, Amsterdam, the Netherlands.

Transplantation
|February 16, 2006
PubMed
Abstract

Insights

Rapamycin inhibits human T cell proliferation and effector functions in vitro but does not induce lasting nonresponsiveness. This study investigated rapamycin

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Rapamycin is known to inhibit cell cycle progression and induce T cell anergy in mice.
  • The effects of rapamycin on human T cells, particularly in the context of alloreactivity, require further investigation.

Purpose of the Study:

  • To determine if rapamycin can induce anergy in human T cells.
  • To investigate the impact of rapamycin on the activation, proliferation, and effector molecule expression of alloresponsive T cells.

Main Methods:

  • Human peripheral blood mononuclear cells were labeled with CFSE and cultured with allogeneic cells in the presence or absence of rapamycin.
  • Flow cytometry was used to analyze T cell surface markers (CD4, CD8, CD25) and intracellular effector molecules (perforin, granzyme B, active caspase-3, TGF-beta).
  • A Bio-Plex assay measured cytokine secretion (IL-2, IL-4, IL-10, IFN-gamma).

Main Results:

  • Rapamycin significantly reduced precursor frequencies of alloreactive CD4+ and CD8+ T cells.
  • Rapamycin induced apoptosis in divided alloreactive T cells, inhibiting T cell expansion.
  • Rapamycin decreased effector molecule production (perforin, granzyme B) and cytotoxicity, but did not induce alloantigen-specific nonresponsiveness upon restimulation.

Conclusions:

  • Rapamycin strongly inhibits proliferation and effector functions of alloreactive human T cells in vitro.
  • Rapamycin does not induce a state of alloantigen-specific nonresponsiveness in human T cells.